Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Exagen (XGN) EBT Margin (2018 - 2025)

Historic EBT Margin for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to 41.09%.

  • Exagen's EBT Margin fell 8900.0% to 41.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 29.86%, marking a year-over-year increase of 4500.0%. This contributed to the annual value of 27.14% for FY2024, which is 178700.0% up from last year.
  • As of Q3 2025, Exagen's EBT Margin stood at 41.09%, which was down 8900.0% from 25.59% recorded in Q2 2025.
  • Over the past 5 years, Exagen's EBT Margin peaked at 19.69% during Q2 2024, and registered a low of 192.87% during Q2 2022.
  • Moreover, its 5-year median value for EBT Margin was 41.09% (2025), whereas its average is 56.55%.
  • In the last 5 years, Exagen's EBT Margin plummeted by -1426900bps in 2022 and then soared by 1574100bps in 2023.
  • Quarter analysis of 5 years shows Exagen's EBT Margin stood at 54.2% in 2021, then plummeted by -117bps to 117.76% in 2022, then surged by 66bps to 40.25% in 2023, then soared by 32bps to 27.46% in 2024, then tumbled by -50bps to 41.09% in 2025.
  • Its EBT Margin stands at 41.09% for Q3 2025, versus 25.59% for Q2 2025 and 24.21% for Q1 2025.